Novo Nordisk (NVO), the maker of popular obesity/diabetes medications Ozempic and Wegovy, warned Thursday that the Trump administration’s proposed tariffs on pharmaceutical goods could cause potential drug shortages and price hikes.

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who can’t get the blockbuster drug through insurance.

Mounting competition in the sector and rising obesity have led the pharmaceutical company to start selling the drug directly to consumers.

Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy.

Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy to reach more people who aren't covered.

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount.